These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 23706796)
1. Not time to RELAX in acute heart failure - Authors' reply. Teerlink JR; Metra M; Lancet; 2013 May; 381(9880):1813-4. PubMed ID: 23706796 [No Abstract] [Full Text] [Related]
2. Not time to RELAX in acute heart failure. Ambrosy AP; Witteles RM Lancet; 2013 May; 381(9880):1813. PubMed ID: 23706797 [No Abstract] [Full Text] [Related]
3. RELAX-AHF: rising from the doldrums in acute heart failure. Konstam MA Lancet; 2013 Jan; 381(9860):5-6. PubMed ID: 23141815 [No Abstract] [Full Text] [Related]
4. Advancing care for acute heart failure--no time to relax. Hernandez AF; Granger CB Lancet; 2009 Apr; 373(9673):1401-2. PubMed ID: 19329180 [No Abstract] [Full Text] [Related]
5. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence. Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514 [TBL] [Abstract][Full Text] [Related]
7. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M; Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816 [TBL] [Abstract][Full Text] [Related]
8. Serelaxin a novel treatment for acute heart failure. Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074 [TBL] [Abstract][Full Text] [Related]
9. Relaxin: a new approach for the treatment of acute congestive heart failure. Grossman J; Frishman WH Cardiol Rev; 2010; 18(6):305-12. PubMed ID: 20926940 [TBL] [Abstract][Full Text] [Related]
10. Representativeness of RELAX-AHF clinical trial population in acute heart failure. Wang TS; Hellkamp AS; Patel CB; Ezekowitz JA; Fonarow GC; Hernandez AF Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):259-68. PubMed ID: 24594552 [TBL] [Abstract][Full Text] [Related]
11. Relaxin: review of biology and potential role in treating heart failure. Teichman SL; Unemori E; Teerlink JR; Cotter G; Metra M Curr Heart Fail Rep; 2010 Jun; 7(2):75-82. PubMed ID: 20424993 [TBL] [Abstract][Full Text] [Related]
12. Relaxin-2 may offer therapeutic advantages in end-stage heart failure. Zhao Z; Liu T; Li G Int J Cardiol; 2012 Jun; 157(3):432-3. PubMed ID: 22541981 [No Abstract] [Full Text] [Related]
13. Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012. von Haehling S Expert Opin Investig Drugs; 2013 Jul; 22(7):933-7. PubMed ID: 23656525 [TBL] [Abstract][Full Text] [Related]
14. The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling. Dschietzig T; Alexiou K; Kinkel HT; Baumann G; Matschke K; Stangl K J Card Fail; 2011 Feb; 17(2):158-66. PubMed ID: 21300306 [TBL] [Abstract][Full Text] [Related]
15. Serelaxin : a potential new drug for the treatment of acute heart failure. Neverova N; Teerlink JR Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798 [TBL] [Abstract][Full Text] [Related]
16. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514 [TBL] [Abstract][Full Text] [Related]
17. Design of the RELAXin in acute heart failure study. Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830 [TBL] [Abstract][Full Text] [Related]
18. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463 [TBL] [Abstract][Full Text] [Related]
19. Targeted biological therapies reach the heart: the case of serelaxin for heart failure. Kumar VA; Wilson SS; Ayaz SI; Levy PD Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301 [TBL] [Abstract][Full Text] [Related]
20. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Voors AA; Davison BA; Felker GM; Ponikowski P; Unemori E; Cotter G; Teerlink JR; Greenberg BH; Filippatos G; Teichman SL; Metra M; Eur J Heart Fail; 2011 Sep; 13(9):961-7. PubMed ID: 21622980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]